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ThiophenolAbstract The urgent need in search of new biological entities to ﬁght back with recent drug-
resistant microbial ﬂora, has led us report a library of s-triazine derivatives. The intermediate
4-((4-chloro-6-methoxy-1,3,5-triazin-2-yl)amino)benzonitrile 3 was substituted with various thio-
phenol, phenol, aniline and piperazine/piperidine/morpholine moieties to furnish the ﬁnal 35 target
compounds i.e. (4a–j), (5a–j), (6a–g) and (7a–h), respectively. These compounds were screened for
in vitro antibacterial evaluation against bacteria (Staphylococcus aureus MTCC 96, Bacillus cereus
MTCC 619, Escherichia coli MTCC 739, and Pseudomonas aeruginosa MTCC 741) and antifungal
activity against fungi (Candida albicans MTCC 183, Aspergillus niger MTCC 282, and Aspergillus
clavatus MTCC 1323). The title compounds were further subjected for antituberculosis activity
against Mycobacterium tuberculosis H37Rv strain using the BACTEC MGIT method. In this bio-
logical evaluation, thiophenol derivatives were found to be more active than the rest (i.e. -Thiophe-
nol > -piperazine > -Aniline > -phenol). The ﬁnal compounds were characterized by FT-IR, 1H
NMR, 13C NMR, mass spectroscopy and elemental analysis.
ª 2014 Production and hosting by Elsevier B.V. on behalf of University of Bahrain. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Multidrug resistant (MDR) strains, a rapid development of
pathogens causing a severe resistance toward currently avail-
able standard drugs, pose a frightening threat by increasing
severe opportunistic microbial infections in past decades
(Gootz, 2010; Niccolai and Tarsi, 1997; Overbye and Barrett,
2005). Such resistant organisms were due for a dramatic andalarming increase in microbial infections which results in
pressing problem worldwide. On the other hand, MDR-
Tuberculosis (TB) and extensively drug-resistant XDR-TB,
caused by some mycobacteria of theMycobacterium tuberculo-
sis complex which most commonly affect the lungs, emerged as
one of the most infectious diseases in the recent era (Ducati
et al., 2006; Gandhi et al., 2010; Udwadia et al., 2012). The lat-
est statistics of World health Organization (WHO) reported
that about one third of the human population were infected
with TB which showed the urgent need to combat such
dilemma (2012).
Surprisingly, 8.7 million new cases of TB were reported in
2011 from which 13% co-infected with HIV (Human Immuno
Synthesis and biological evaluation of novel s-triazine based aryl/heteroaryl entities 9Deﬁciency); 1.4 million people died from TB, including almost
one million deaths among HIV-negative individuals and 0.4
million people allied to HIV-positive which scores around
25% death due to TB (2013). In view of the above, conse-
quences of these problems highlight the urgent need to develop
new agents with speciﬁc activity with increased potency to sus-
tain a pool of new bioactive entities. Therefore, design and
synthesis of new compounds likely to be unaffected by existing
resistance mechanisms are an area of immense signiﬁcance for
medicinal chemists.
Owing to a wide range of biological applications, s-triazine
nucleus has received an immense attention among chemists
through fertile source of pharmacological activities such as
antibacterial (Bhushan Singh et al., 2012; Gahtori et al.,
2012b; Kumar Ghosh et al., 2012), antimalarial (Gahtori
et al., 2012a), antiprotozoal (Baliani et al., 2005), antifungal
(Singh et al., 2012), anticancer (Menicagli et al., 2004), antimy-
cobacterial (Patel et al., 2012), and antiviral (Chen et al., 2012).
In addition to this several s-triazine derivatives bearing
p-amino benzonitrile moiety have been found to possess an
enhanced antimicrobial proﬁle and improved antitubercular
(Patel et al., 2011b) and profound anticancer activity (Patel
et al., 2011a) as well. Consequences of such potential effects
of triazine and an imperative need in search of new chemical
entities lead us to synthesize some biologically efﬁcient
molecules.
Recently our research group has reported 2,4,6-trisubsti-
tuted triazine derivatives endowing promising biological activ-
ity (Modh et al., 2012a,b,c, 2013a,b; Patel et al., 2012,
2011a,b); hence it is worthy to synthesize novel compounds
which elicit a series of antimicrobial and anti tuberculosis
agents. Recent studies have conﬁrmed that several s-triazine
derivatives bearing morpholine, piperidine and some pipera-
zine moieties are effective againstM. tuberculosisH37Rv strain
(Sunduru et al., 2010). Prompted by such facts it is worthy to
envisage that combination of such bioactive moieties in a com-
pact system may arise with new biologically active agents. We
introduced synthetic strategy to acquire triazine nucleus with
biolabile derivatives viz. phenol, thiophenol, aniline and
piperazine/piperidine/morpholine. Target compounds were
rationalized and designed using the hits obtained from the
(piperazinyl/piperidinyl)-s-triazines derivatives (Patel et al.,
2011a), which were previously reported for their antimicrobial,
antimycobacterial and anticancer activities besides this, com-
pound R129385 (Das et al., 2004) with s-triazine nucleus was
reported as an effective antiviral agent (Fig. 1). Adopting all
such criteria, herewith, a library of 35 s-triazine based com-
pounds were synthesized and evaluated for their biological
potential which may lead to future prospects in drug design
and discovery.
2. Experimental section
2.1. Materials and methods
All chemicals as well as solvents were procured from sigma
Aldrich, Merck and Fluka. Solvents taken were of analytical
grade and used without further puriﬁcation. All reactions were
routinely checked by TLC. TLC was performed on aluminum-
backed silica gel plates (Silica gel 60 F254 grade, Merck DC)
with spots visualized by UV light. Column chromatographywas performed on silica gel LC 60A (70–200 l). Melting points
were determined in open capillaries on a Veego electronic
apparatus VMP-D (Veego Instrument Corporation, Mumbai,
India) and are uncorrected. FT-IR spectra were recorded on a
perkin–Elmer 257 spectrometer using KBr disks. 1H NMR and
13C NMR spectra were recorded on a Bruker 400 MHz model
spectrometer using DMSO-d6 as a solvent and TMS as an
internal standard. The chemical shifts were reported as parts
per million (ppm) downﬁeld from TMS (Me4Si) with
1H reso-
nant frequency of 400 MHz and 13C resonant frequency of
100 MHz. Purity of all tested compounds was ensured on the
basis of their elemental analyses (C, H, N) and were performed
using a Heraeus Carlo Erba 1180 CHN analyzer (Hanau,
Germany). The electron spray mass spectra were recorded on
a triple quadrupole mass spectrometer with the ionization
potential of 70 eV Fig. 2.
2.2. Chemistry: general methods
2.2.1. Synthesis of 2,4-dichloro-6-methoxy-1,3,5-triazine (2)
A mixture of 2,4,6-trichloro-1,3,5-triazine 1 (5.0 g, mol) and
sodium bicarbonate (2.5 g, 0.02982 mol) in methanol (10 mL)
was stirred at 0–5 C for 4 h. The progress of the reaction
was monitored by TLC using hexane:ethyl acetate (4:1) solvent
system as an eluent. After the completion of the reaction, the
reaction mass was poured into crushed ice. The solid was sep-
arated, washed with cold water, dried and recrystallized from
ethanol to give compound 2 (Dudley et al., 1951). Yield:
79%; m.p. 88–90 C; IR (KBr cm1): 2815 (–OCH3), 826
(C3N3, s-triazine);
1H NMR (400 MHz, DMSO-d6): d 3.77
(s, 3H–Ar–OCH3);
13C NMR 179.8, 167.5, 58.3; ESI-MS
(M+1): 180.99.
2.2.2. Synthesis of 4-((4-chloro-6-methoxy-1,3,5-triazin-2-
yl)amino)benzonitrile (3)
To a stirred solution of compound 2 (5.0 g, 0.02778 mol) and
sodium bicarbonate (2.56 g, 0.03056 mol) in THF (20 mL), a
solution of 4-amino benzonitrile (3.28 g, 0.02778 mol) was
added and stirred for 6 h at room temperature. The progress
of the reaction was monitored by TLC using toluene:acetone
(4:1) solvent system as an eluent. After the completion of the
reaction, resultant mixture was poured into crushed ice. The
solid product obtained was ﬁltered, washed with distilled
water, dried and puriﬁed by column chromatography using
toluene:acetone solvent system as an eluent. Yield: 85%;
m.p.167 C; IR (KBr cm1): 3372 (N–H), 2210 (C‚N), 845
(C3N3, s-triazine); 1H NMR (400 MHz, DMSO-d6): DMSO-
d6: d 2.97 (s, 3H–Ar–OCH3), 9.8 (s,1H, –NH);
13C NMR
177.1, 169.2, 168.9, 144.6, 135.9, 119.7, 118.5, 105.1, 54.8;
ESI-MS (m/z): 262.67.
2.2.3. General procedure for the preparation of ((4-methoxy-6-
(substituted phenylthio)-1,3,5-triazin-2-yl)amino)benzonitrile
(4a–j)
A stirred mixture of appropriate thiophenol (0.0191 mol),
4-((4-chloro-6-methoxy-1,3,5-triazin-2-yl)amino)benzonitrile 3
(5.0 g, 0.0191 mol) and anhydrous K2CO3 (2.92 g,
0.0211 mol) in DMF (20 mL) was reﬂuxed for 20 h. The pro-
gress of the reaction was monitored by TLC using toluene:ace-
tone (7:3) solvent system as an eluent. After the completion of
the reaction, the reaction mass was poured into ice. The
Figure 1 Scheme. Synthetic route for novel s-triazine based aryl/
heteroaryl derivatives.
10 N.S. Mewada et al.product was extracted with 25 mL ethyl acetate and then the
organic layer was washed with ﬁrst brine and then with water.
The organic layer was separated, dried over Na2SO4 and con-
centrated to dryness to give a yellow solid, which was re-crys-
tallized from n-hexane to give light yellow powder.
2.2.3.1. 4-((4-Methoxy-6-(phenylthio)-1,3,5-triazin-2-yl)amino)
benzonitrile (4a). Yield: 83%; m.p. 166 C; IR (KBr cm1):
3271 (N–H), 2909 (C–H), 2240 (C„N), 1305 (C–N in 2 aro-
matic amine), 1210 (C–O), 1100 (C–S), 830 (C3N3–s-triazine);
1H NMR (400 MHz, DMSO-d6): d ppm 7.54 (d, J= 7.5 Hz,
2H), 7.25–6.89 (m, 7H), 6.33 (s, 1H), 3.82 (s, 3H); 13C NMR
(100 MHz, DMSO-d6): d 191.4, 177.9, 166.3, 143.6, 134.4,
132.1, 129.9, 128.1, 126.6, 119.2, 118.1, 103.3, 54.7; Anal.
Calcd. for C17H13N5OS: C, 60.88; H, 3.91; N, 20.88; O, 4.77;Figure 2 The strategy for dS, 9.56, Found: C, 60.74; H, 3.79; N, 20.78; O, 4.67; S, 9.45;
ESI-MS (M+1): 336.08.
2.2.3.2. 4-((4-((2-Chlorophenyl)thio)-6-methoxy-1,3,5-triazin-
2-yl)amino)benzonitrile (4b). Yield: 79%; m.p. 183 C; IR
(KBr cm1): 3260 (N–H), 2890 (C–H), 2231 (C„N), 1309
(C–N in 2 aromatic amine), 1221 (C–O), 1121 (C–S), 841
(C3N3–s-triazine), 564 (C–Cl);
1H NMR (400 MHz DMSO-
d6): d 7.57 (d, J= 7.5 Hz, 2H), 7.34–7.12 (m, 4H), 7.08–7.01
(m, 2H), 6.09 (s, 1H), 3.84 (s, 3H); 13C NMR (100 MHz,
DMSO-d6): d 189.4, 179.9, 168.3, 148.6, 137.8, 134.8, 132.4,
130.1, 127.6, 129.9, 126.8, 119.2, 118.2, 103.3, 54.1; Anal.
Calcd. for C17H12ClN5OS: C, 55.21; H, 3.27; Cl, 9.59; N,
18.94; O, 4.33; S, 8.67, Found: C, 55.11; H, 3.17; Cl, 9.49;
N, 18.83; O, 4.21; S, 8.55; ESI-MS (M+1): 370.83.
2.2.3.3. 4-((4-((3-Chlorophenyl)thio)-6-methoxy-1,3,5-triazin-
2-yl)amino)benzonitrile (4c). Yield: 70%; m.p. 174 C; IR
(KBr cm1): 3283 (N–H), 2921 (C–H), 2228 (C„N), 1312
(C–N in 2 aromatic amine), 1215 (C–O), 1110 (C–S) 822
(C3N3–s-triazine), 594 (C–Cl);
1H NMR (400 MHz DMSO-
d6): d 7.51 (d, J= 7.5 Hz, 2H), 7.46 (t, J= 1.3 Hz, 1H),
7.24–7.06 (m, 5H), 6.12 (s, 1H), 3.83 (s, 3H); 13C NMR
(100 MHz, DMSO-d6): d 193.4, 174.3, 164.8, 149.7, 135.2,
133.7, 131.2, 130.4, 129.6, 127.2, 126.2, 119.2, 118.6, 103.9,
54.1; Anal. Calcd. for C17H12ClN5OS; C, 55.21; H, 3.27; Cl,
9.59; N, 18.94; O, 4.33; S, 8.67, Found: C, 55.10; H, 3.17;
Cl, 9.49; N, 18.84; O, 4.23; S, 8.57; ESI-MS (M+1): 370.83.
2.2.3.4. 4-((4-((4-Chlorophenyl)thio)-6-methoxy-1,3,5-triazin-
2-yl)amino)benzonitrile (4d). Yield: 82%; m.p. 180 C; IResign of title compounds.
Synthesis and biological evaluation of novel s-triazine based aryl/heteroaryl entities 11(KBr cm1): 3273 (N–H), 2890 (C–H), 2240 (C„N), 1309 (C–
N in 2 aromatic amine), 878 (C3N3–s-triazine), 1247 (C–O),
580 (C–Cl), 1197 (C–S); 1H NMR (400 MHz DMSO-d6): d
7.41 (d, J= 7.5 Hz, 2H), 7.28 (d, J= 7.5 Hz, 2H), 7.20 (dd,
J= 7.5, 4.4 Hz, 4H), 6.29 (s, 1H), 3.79 (s, 3H); 13C NMR
(100 MHz, DMSO-d6): d 181.1, 172.9, 161.3, 140.6, 135.7,
131.4, 129.4, 127.4, 126.3, 119.8, 118.2, 103.7, 56.9; Anal.
Calcd. for C17H12ClN5OS; C, 55.21; H, 3.27; Cl, 9.59; N,
18.94; O, 4.33; S, 8.67, Found: C, 55.21; H, 3.27; Cl, 9.59;
N, 18.94; O, 4.33; S, 8.67; ESI-MS (M+1): 370.83.
2.2.3.5. 4-((4-Methoxy-6-(o-tolylthio)-1,3,5-triazin-2-yl)amino)
benzonitrile (4e). Yield: 77%; m.p. 179 C; IR (KBr cm1):
3212 (N–H), 2798 (C–H), 2264 (C„N), 1397 (C–N in 2 aro-
matic amine), 812 (C3N3–s-triazine), 1264 (C–O), 978 (C–S);
1H NMR (400 MHz, DMSO-d6): d 7.53 (d, J= 7.5 Hz, 2H),
7.50–7.16 (m, 3H), 7.14–6.89 (m, 3H), 6.06 (s, 1H), 3.83 (s,
3H), 2.41 (s, 3H); 13C NMR (100 MHz, DMSO-d6): d 195.1,
171.8, 167.3, 156.7, 144.6, 136.9, 133.4, 130.8, 125.6, 123.2,
119.4, 118.6, 115.2, 103.7, 53.9, 20.1; Anal. Calcd. for C17H12-
FN5OS: C, 57.78; H, 3.42; F, 5.38; N, 19.82; O, 4.53; S, 9.07,
Found: C, 57.65; H, 3.31; F, 5.25; N, 19.78; O, 4.41; S, 9.10;
ESI-MS (M+1): 350.41.
2.2.3.6. 4-((4-Methoxy-6-(m-tolylthio)-1,3,5-triazin-2-yl)amino)
benzonitrile (4f). Yield: 62%; m.p. 154 C; IR (KBr cm1):
3376 (N–H), 2815 (C–H), 2120 (C„N), 1264 (C–N in 2 aro-
matic amine), 892 (C3N3–s-triazine), 1254 (C–O), 1163 (C–S);
1H NMR (400 MHz, DMSO-d6): d 7.62–7.47 (m, 2H), 7.30
(s, 1H), 7.22–7.18 (m, 3H), 7.13 (s, 1H), 6.95 (s, 1H), 6.30 (s,
1H), 3.86–3.82 (m, 3H), 2.36–2.32 (m, 3H); 13C NMR
(100 MHz, DMSO-d6): d 192.7, 176.1, 163.2, 154.2, 143.1,
137.9, 134.6, 130.9, 128.6, 124.2, 122.6, 119.7, 118.9, 103.1,
59.4, 21.1; Anal. Calcd. for C17H12FN5OS: C, 57.78; H, 3.42;
F, 5.38; N, 19.82; O, 4.53; S, 9.07, Found: C, 57.69; H, 3.32;
F, 5.28; N, 19.72; O, 4.44; S, 9.05; ESI-MS (M+1): 350.41.
2.2.3.7. 4-((4-Methoxy-6-(p-tolylthio)-1,3,5-triazin-2-
yl)amino)benzonitrile (4g). Yield: 76%; m.p. 137 C; IR
(KBr cm1): 3346 (N–H), 2912 (C–H), 2194 (C„N), 1245
(C–N in 2 aromatic amine), 866 (C3N3–s-triazine), 1226 (C–
O), 1167 (C–S): 1H NMR (400 MHz, DMSO-d6): d 7.56 (d,
J= 7.5 Hz, 2H), 7.27 (d, J= 7.5 Hz, 2H), 7.21 (d,
J= 7.5 Hz, 2H), 7.05 (d, J= 7.5 Hz, 2H), 6.30 (s, 1H), 3.78
(s, 3H), 2.32 (s, 3H); 13C NMR (100 MHz, DMSO-d6): d
191.6, 175.3, 166.8, 154.9, 143.6, 142.9, 136.1, 133.4, 129.7,
119.7, 118.2, 103.7, 54.2, 23.9; Anal. Calcd. for C17H12FN5OS:
C, 57.78; H, 3.42; F, 5.38; N, 19.82; O, 4.53; S, 9.07, Found: C,
57.66; H, 3.30; F, 5.26; N, 19.70; O, 4.50; S, 9.10; ESI-MS
(M+1): 350.41.
2.2.3.8. 4-((4-((2-Fluorophenyl)thio)-6-methoxy-1,3,5-triazin-
2-yl)amino)benzonitrile (4h). Yield: 68%; m.p. 146 C; IR
(KBr cm1): 3243 (N–H), 2887 (C–H), 2251 (C„N), 1309
(C–N in 2 aromatic amine), 814 (C3N3–s-triazine), 1210 (C–
O), 1320 (C–F), 900 (C–S) 1H NMR (400 MHz, DMSO-d6):
d 7.61–7.46 (m, 2H), 7.31–7.14 (m, 3H), 7.11 (s, 1H), 6.93 (d,
J= 10.7 Hz, 2H), 6.29 (s, 1H), 3.78–3.74 (m, 3H); 13C NMR
(100 MHz, DMSO-d6): d 188.4, 176.9, 168.9, 158.2, 143.5,
134.6, 128.7, 127.4, 126.1, 124.7, 119.2, 118.7, 115.4, 103.7,
54.8; Anal. Calcd. for C18H15N5OS; C, 61.87; H, 4.33; N,20.04; O, 4.58; S, 9.18, Found: C, 61.75; H, 4.21; N, 20.10;
O, 4.44; S, 9.07; ESI-MS (M+1): 354.37.
2.2.3.9. 4-((4-((3-Fluorophenyl)thio)-6-methoxy-1,3,5-triazin-
2-yl)amino)benzonitrile (4i). Yield: 82%; m.p. 164 C; IR
(KBr cm1): 3273 (N–H), 2840 (C–H), 2240 (C„N), 1344
(C–N in 2 aromatic amine), 897 (C3N3–s-triazine), 1364 (C–
F), 1296 (C–O), 964 (C–S): 1H NMR (400 MHz, DMSO-d6):
d 7.53 (d, J= 7.5 Hz, 2H), 8.59–6.81 (m, 8H), 6.15 (s, 1H),
3.83 (s, 3H); 13C NMR (100 MHz, DMSO-d6): d 196.3,
177.5, 167.8, 161.9, 145.8, 138.1, 135.2, 128.7, 124.1, 119.2,
118.7, 114.7, 112.3, 101.3, 52.1; Anal. Calcd. For C18H15N5OS
C, 61.87; H, 4.33; N, 20.04; O, 4.58; S, 9.18, Found: C, 61.74;
H, 4.23; N, 20.11; O, 4.43; S, 9.05; ESI-MS (M+1): 354.37.
2.2.3.10. 4-((4-((4-Fluorophenyl)thio)-6-methoxy-1,3,5-tria-
zin-2-yl)amino)benzonitrile (4j). Yield: 65%; m.p. 183 C; IR
(KBr cm1): 3245 (N–H), 2863 (C–H), 2221 (C„N), 1364
(C–N in 2 aromatic amine), 897 (C3N3–s-triazine), 1252 (C–
O), 1347 (C–F), 946 (C–S): 1H NMR (400 MHz, DMSO-d6):
d 7.49 (d, J= 7.5 Hz, 2H), 7.37–7.28 (m, 2H), 7.21 (d,
J= 7.5 Hz, 2H), 6.91 (t, J= 7.7 Hz, 2H), 6.30 (s, 1H), 3.85
(s, 3H); 13C NMR (100 MHz, DMSO-d6): d 192.6, 178.3,
168.3, 154.1, 141.6, 131.4, 129.2, 127.4, 120.4, 118.4, 114.9,
105.7, 56.5; Anal. Calcd. for C17H12N5OS: C, 61.06; H, 3.62;
N, 20.94; O, 4.78; S, 9.59, Found: C, 61.10; H, 3.52; N,
20.83; O, 4.66; S, 9.48; ESI-MS (M+1): 354.37.
2.2.4. General procedure for the preparation of
4-((4-(substituted phenoxy)-6-methoxy-1,3,5-triazin-2-yl)
amino)benzonitrile (5a–j)
A mixture of 4-((4-chloro-6-methoxy-1,3,5-triazin-2-
yl)amino)benzonitrile 3 (5.0 g, 0.0191 mol), appropriate phe-
nol (0.0191 mol) and sodium hydroxide (0.93 g, 0.0232 mol)
in THF (20 mL) was stirred and reﬂuxed for 5 h. The progress
of the reaction was monitored by TLC using ethyl acetate:hex-
ane (4:1) solvent system as an eluent. After the completion of
the reaction, resultant mixture was poured into crushed ice.
The solid product obtained was ﬁltered, washed with distilled
water, dried and puriﬁed by column chromatography using
ethyl acetate:hexane solvent as an eluent.
2.2.4.1. 4-((4-Methoxy-6-phenoxy-1,3,5-triazin-2-yl)amino)
benzonitrile (5a). Yield: 82%; m.p. 140 C; IR (KBr cm1):
3397 (N–H), 2788 (C–H), 2164 (C„N), 1268 (C–N in 2 aro-
matic amine), 866 (C3N3–s-triazine), 1234 (C–O);
1H NMR
(400 MHz, DMSO-d6): d 7.55 (d, J= 7.5 Hz, 2H), 7.26–7.12
(m, 4H), 6.98–6.85 (m, 3H), 6.27 (s, 1H), 3.81 (s, 3H); 13C
NMR (100 MHz, DMSO-d6): d 195.4, 173.9, 167.8, 152.8,
144.1, 136.4, 128.9, 123.6, 122.8, 119.3, 118.7, 104.1, 56.8;
Anal. Calcd. for C17H13N5O2: C, 63.94; H, 4.10; N, 21.93;
O, 10.02, Found: C, 63.80; H, 4.00; N, 21.82; O, 10.12; ESI-
MS (M+1): 320.11.
2.2.4.2. 4-((4-Methoxy-6-(o-tolyloxy)-1,3,5-triazin-2-
yl)amino)benzonitrile (5b). Yield: 73%; m.p. 168 C; IR
(KBr cm1): 3245 (N–H), 2858 (C–H), 2232 (C„N), 1301
(C–N in 2 aromatic amine), 864 (C3N3–s-triazine), 1214 (C–
O); 1H NMR (400 MHz, DMSO-d6): d 7.55 (d, J= 7.5 Hz,
2H), 7.22 (d, J= 7.5 Hz, 2H), 7.06 (ddd, J= 14.3, 7.4,
1.5 Hz, 2H), 6.92–6.82 (m, 2H), 6.27 (s, 1H), 3.81 (s, 3H),
12 N.S. Mewada et al.2.35 (s, 3H); 13C NMR (100 MHz, DMSO-d6): d 188.3, 175.9,
164.3, 157.2, 154.9, 146.1, 134.3, 129.2, 127.6, 124.8, 119.1,
118.8, 114.2, 103.8, 58.1, 18.5; Anal. Calcd. for C18H15N5O2:
C, 64.86; H, 4.54; N, 21.01; O, 9.60, Found: C, 64.75; H,
4.44; N, 21.11; O, 9.51; ESI-MS (M+1): 334.12.
2.2.4.3. 4-((4-Methoxy-6-(m-tolyloxy)-1,3,5-triazin-2-
yl)amino)benzonitrile (5c). Yield: 74%, m.p. 139 C; IR
(KBr cm1): 3369 (N–H), 2887 (C–H), 2186 (C„N), 1362
(C–N in 2 aromatic amine), 826 (C3N3–s-triazine), 1171 (C–
O); 1H NMR (400 MHz, DMSO-d6): d 7.47 (d, J= 7.5 Hz,
2H), 7.22 (d, J= 7.5 Hz, 2H), 7.12 (t, J= 7.4 Hz, 1H),
6.85–6.74 (m, 3H), 6.27 (s, 1H), 3.81 (s, 3H), 2.34 (s, 3H);
13C NMR (100 MHz, DMSO-d6): d 186.9, 179.2, 162.8,
158.5, 151.3, 145.7, 133.4, 127.6, 124.9, 121.1, 120.6, 116.8,
112.3, 106.1, 57.4, 22.6; Anal. Calcd. for C18H15N5O2; C,
64.86; H, 4.54; N, 21.01; O, 9.60, Found: C, 64.73; H, 4.44;
N, 21.00; O, 9.58; ESI-MS (M+1): 334.12.
2.2.4.4. 4-((4-Methoxy-6-(p-tolyloxy)-1,3,5-triazin-2-
yl)amino)benzonitrile (5d). Yield: 69%; m.p. 161 C; IR
(KBr cm1): 3361 (N–H), 2859 (C–H), 2114 (C„N), 1285
(C–N in 2 aromatic amine), 897 (C3N3–s-triazine), 1216 (C–
O); 1H NMR (400 MHz, DMSO-d6): d 7.22 (d, J= 7.5 Hz,
2H), 7.04 (d, J= 7.5 Hz, 2H), 6.84 (d, J= 7.5 Hz, 2H), 6.27
(s, 1H), 8.35 to 2.37 (m, 15H), 7.50 to 2.37 (m, 13H),
3.81 (s, 3H), 2.33 (s, 3H); 13C NMR (100 MHz, DMSO-d6):
d 191.3, 173.9, 162.9, 156.5, 152.3, 147.4, 132.1, 129.4, 121.6,
119.2, 114.1, 104.3, 58.4, 20.4; Anal. Calcd. for C18H15N5O2:
C, 64.86; H, 4.54; N, 21.01; O, 9.60, Found: C, 64.76; H,
4.42; N, 20.95; O, 9.50; ESI-MS (M+1): 334.12.
2.2.4.5. 4-((4-(2-Fluorophenoxy)-6-methoxy-1,3,5-triazin-2-
yl)amino)benzonitrile (5e). Yield: 68%; m.p. 166 C; IR
(KBr cm1): 3297 (N–H), 2879 (C–H), 2144 (C„N), 1321
(C–N in 2 aromatic amine), 844 (C3N3–s-triazine), 1164 (C–
O), 1341 (C–F); 1H NMR (400 MHz, DMSO-d6): d 7.56 (d,
J= 7.5 Hz, 2H), 7.22 (d, J= 7.5 Hz, 2H), 7.07–6.64 (m,
4H), 6.26 (s, 1H), 3.79 (s, 3H); 13C NMR (100 MHz,
DMSO-d6): d 191.9, 178.3, 164.3, 154.8, 152.3, 141.6, 138.2,
127.2, 125.1, 121.4, 119.4, 117.2, 113.7, 104.3, 56.7; Anal.
Calcd. for C17H12FN5O2 C, 60.53; H, 3.59; F, 5.63; N,
20.76; O, 9.49, Found: C, 60.42; H, 3.47; F, 5.53; N, 20.65;
O, 9.33; ESI-MS (M+1): 338.10.
2.2.4.6. 4-((4-(3-Fluorophenoxy)-6-methoxy-1,3,5-triazin-2-
yl)amino)benzonitrile (5f). Yield: 81%; m.p. 175 C; IR
(KBr cm1): 3364 (N–H), 2851 (C–H), 2261 (C„N), 1327
(C–N in 2 aromatic amine), 832 (C3N3–s-triazine), 1234 (C–
O), 1399 (C–F); 1H NMR (400 MHz, DMSO-d6): d 7.51 (d,
J= 7.5 Hz, 2H), 7.26–7.12 (m, 3H), 6.68 (ddd, J= 14.2, 5.7,
1.3 Hz, 3H), 6.27 (s, 1H), 3.81 (s, 3H); 13C NMR (100 MHz,
DMSO-d6): d 194.7, 173.9, 161.3, 154.6, 153.2, 148.6, 134.3,
127.7, 125.1, 123.6, 119.8, 118.4, 115.4, 108.1, 57.2; Anal.
Calcd. for C17H12FN5O2 C, 60.53; H, 3.59; F, 5.63; N,
20.76; O, 9.49, Found: C, 60.41; H, 3.48; F, 5.54; N, 20.64;
O, 9.32; ESI-MS (M+1): 338.10.
2.2.4.7. 4-((4-(4-Fluorophenoxy)-6-methoxy-1,3,5-triazin-2-yl)
amino)benzonitrile (5g). Yield: 73%; m.p. 175 C; IR (KBr
cm1): 3313 (N–H), 2812 (C–H), 2245 (C„N), 1297 (C–N in2 aromatic amine), 889 (C3N3–s-triazine), 1145 (C–O), 1362
(C–F); 1H NMR (400 MHz, DMSO-d6): d 7.57 (d,
J= 7.5 Hz, 2H), 7.26 (d, J= 7.5 Hz, 2H), 6.96–6.83 (m,
4H), 6.27 (s, 1H), 3.81 (s, 3H); 13C NMR (100 MHz,
DMSO-d6): d 192.9, 174.3, 163.3, 157.1, 151.5, 144.2, 133.7,
125.4, 120.1, 117.8, 114.6, 107.4, 56.9; Anal. Calcd. for C17H12-
FN5O2 C, 60.53; H, 3.59; F, 5.63; N, 20.76; O, 9.49, Found: C,
60.45; H, 3.50; F, 5.57; N, 20.66; O, 9.34; ESI-MS (M+1):
338.10.
2.2.4.8. 4-((4-(2-Chlorophenoxy)-6-methoxy-1,3,5-triazin-2-yl)
amino)benzonitrile (5h). Yield: 64%; m.p. 136 C; IR (KBr
cm1): 3293 (N–H), 2866 (C–H), 2164 (C„N), 1284 (C–N in
2 aromatic amine), 837 (C3N3–s-triazine), 1164 (C–O), 596
(C–Cl); 1H NMR (400 MHz, DMSO-d6): d 7.50 (d,
J= 7.5 Hz, 2H), 7.29–7.11 (m, 3H), 7.08 (td, J= 7.5, 1.4 Hz,
1H), 6.91–6.78 (m, 2H), 6.29 (s, 1H), 3.80 (s, 3H); 13C NMR
(100 MHz, DMSO-d6): d 195.7, 176.3, 164.8, 155.1, 146.8,
133.4, 131.7, 129.2, 127.4, 124.6, 122.9, 120.1, 117.8, 106.3,
57.9; Anal. Calcd. For C17H12ClN5O2: C, 57.72; H, 3.42; Cl,
10.02; N, 19.80; O, 9.05, Found: C, 57.61; H, 3.30; Cl, 10.15;
N, 19.69; O, 8.96; ESI-MS (M+1): 354.07.
2.2.4.9. 4-((4-(3-Chlorophenoxy)-6-methoxy-1,3,5-triazin-2-yl)
amino)benzonitrile (5i). Yield: 68%; m.p. 167 C; IR (KBr
cm1): 3212 (N–H), 2832 (C–H), 2156 (C„N), 1244 (C–N in
2 aromatic amine), 846(C3N3–s-triazine), 1161 (C–O), 569
(C–Cl); 1H NMR (400 MHz, DMSO-d6): d 7.58 (d,
J= 7.5 Hz, 2H), 7.22 (d, J= 7.5 Hz, 2H), 7.12 (t, J= 7.5 Hz,
1H), 7.01–6.92 (m, 2H), 6.79 (dt, J= 7.3, 1.4 Hz, 1H), 6.27 (s,
1H), 3.80 (s, 3H); 13C NMR (100 MHz, DMSO-d6): d 194.1,
176.9, 164.2, 153.2, 147.2, 139.5, 134.4, 131.9, 126.1, 122.6,
120.2, 119.5, 118.3, 103.2, 56.3; Anal. Calcd. for C17H12ClN5O2:
C, 57.72; H, 3.42; Cl, 10.02; N, 19.80; O, 9.05, Found: C,
57.60; H, 3.31; Cl, 10.14; N, 19.71; O, 8.97; ESI-MS (M+1):
354.07.
2.2.4.10. 4-((4-(4-Chlorophenoxy)-6-methoxy-1,3,5-triazin-2-yl)
amino)benzonitrile (5j). Yield: 79%; m.p. 164 C; IR (KBr
cm1): 3361 (N–H), 2843 (C–H), 2120 (C„N), 1320 (C–N in
2 aromatic amine), 829 (C3N3–s-triazine), 1156 (C–O), 561
(C–Cl); 1H NMR (400 MHz, DMSO-d6): d 7.49 (d,
J= 7.5 Hz, 2H), 7.21 (dd, J= 13.6, 7.5 Hz, 4H), 6.83 (d,
J= 7.5 Hz, 2H), 6.27 (s, 1H), 3.81 (s, 3H); 13C NMR
(100 MHz, DMSO-d6): d 189.2, 177.3, 161.8, 150.9, 145.2,
136.4, 132.9, 130.2, 120.1, 118.6, 114.2, 107.2, 57.4; Anal.
Calcd. for C17H12ClN5O2: C, 57.72; H, 3.42; Cl, 10.02; N,
19.80; O, 9.05, Found: C, 57.62; H, 3.32; Cl, 10.12; N, 19.70;
O, 8.95; ESI-MS (M+1): 354.07.
2.2.5. General procedure for the synthesis of 4-(4-methoxy-6-
phenyl amino-[1,3,5 trazine-2-ylamino)-benzonitrile (6a–g)
A stirred solution of 4-((4-chloro-6-methoxy-1,3,5-triazin-2-
yl)amino)benzonitrile 3 (5.0 g, 0.0191 mol), appropriate aniline
(0.0191 mol) and sodium bicarbonate (1.77 g, 0.0210 mol) in
THF (20 mL) was reﬂuxed for 5 h. The progress of reaction
was monitored by TLC using hexane:ethyl acetate (4:1) as an
eluent. After the completion of reaction, the reﬂuxed content
was poured into crushed ice. The solid product obtained was
ﬁltered and dried. The crude product was puriﬁed by crystalli-
zation from acetone to get the title compound.
Synthesis and biological evaluation of novel s-triazine based aryl/heteroaryl entities 132.2.5.1. 4-((4-Methoxy-6-(phenylamino)-1,3,5-triazin-2-yl)
amino)benzonitrile (6a). Yield: 78%; m.p. 113 C; IR (KBr
cm1): 3278 (N–H), 1248 (C–O–C), 1310 (CN), 3085 (Aro-
matic CH str), 836 (s-triazine C–N str.); 1H NMR
(400 MHz, DMSO-d6): d 7.60 (d, J= 7.5 Hz, 2H), 7.30–7.16
(m, 4H), 7.03–6.92 (m, 3H), 4.79 (s, 1H), 4.51 (s, 1H), 3.87
(s, 3H); 13C NMR (100 MHz, DMSO-d6): d 189.7, 172.3,
166.3, 148.8, 136.2, 132.7, 128.7, 122.1, 121.6, 118.4, 113.9,
103.1, 56.8; Anal. Calcd. for C17H14N6O: C, 64.14; H, 4.43;
N, 26.40; O, 5.03, Found: C, 62.14; H, 4.33; N, 26.40; O,
5.03; ESI-MS (M+1): 319.12.
2.2.5.2. 4-((4-((2-Chlorophenyl)amino)-6-methoxy-1,3,5-tria-
zin-2-yl)amino)benzonitrile (6b). Yield: 81%; m.p. 144 C; IR
(KBr cm1): 3276 (NH), 1245 (C–O–C), 1314 (CN), 3064
(Aromatic CH str), 849 (s-triazine C–N str.); 1H NMR
(400 MHz, DMSO-d6): d 7.60 (d, J= 7.5 Hz, 2H), 9.47–7.22
(m, 3H), 9.47–7.08 (m, 6H), 9.47–7.01 (m, 7H), 9.47–6.94 (m,
7H), 9.47–5.22 (m, 9H), 4.77 (s, 1H), 3.92 (s, 3H); 13C NMR
(100 MHz, DMSO-d6): d 189.8, 170.9, 167.7, 145.8, 140.5,
137.6, 135.1, 130.8, 127.6, 122.1, 120.6, 118.5, 112.4, 102.1,
52.7; Anal. Calcd. for C17H13ClN6O: C, 57.88; H, 3.71; Cl,
10.05; N, 23.82; O, 4.54, Found: C, 56.84; H, 3.69; Cl, 10.05;
N, 22.82; O, 4.52; ESI-MS (M+1): 353.08.
2.2.5.3. 4-((4-((3-Chlorophenyl)amino)-6-methoxy-1,3,5-tria-
zin-2-yl)amino)benzonitrile (6c). Yield: 70%; m.p. 138 C; IR
(KBr cm1): 3259 (NH), 1259 (C–O–C), 1325 (CN), 3059
(Aromatic CH str), 831 (s-triazine C–N str.); 1H NMR
(400 MHz, DMSO-d6): d 7.55 (d, J= 7.5 Hz, 2H), 7.24–7.16
(m, 3H), 7.02–6.92 (m, 3H), 4.70 (s, 1H), 4.60 (s, 1H), 3.88
(s, 3H); 13C NMR (100 MHz, DMSO-d6): d 193.3, 174.3,
162.8, 146.3, 143.5, 135.8, 133.1, 128.6, 126.6, 122.1, 118.5,
116.6, 112.3, 106.1, 58.3; Anal. Calcd. for C17H13ClN6O: C,
57.88; H, 3.71; Cl, 10.05; N, 23.82; O, 4.54, Found: C, 57.70;
H, 3.55; Cl, 10.05; N, 23.83; O, 4.55; ESI-MS (M+1): 353.08.
2.2.5.4. 4-((4-Methoxy-6-(o-tolylamino)-1,3,5-triazin-2-yl)
amino)benzonitrile (6d). Yield: 72%; m.p. 164 C; IR (KBr
cm1): 3255 (NH), 1256 (C–O–C), 1338 (CN), 3052 (Aromatic
CH str), 831 (s-triazine C–N str.); 1H NMR (400 MHz,
DMSO-d6): d 7.84 (t, J= 177.8 Hz, 2H), 9.35–7.07 (m, 6H),
9.35–6.95 (m, 7H), 9.35–4.93 (m, 8H), 8.33–11.38 (m, 16H),
7.65–11.38 (m, 16H), 4.65 (s, 1H), 4.30 (s, 1H), 3.87 (s, 3H),
2.31 (s, 3H); 13C NMR (100 MHz, DMSO-d6): d 194.3,
176.2, 164.4, 146.1, 142.3, 139.8, 135.1, 130.0, 128.2, 126.6,
121.6, 119.3, 118.2, 105.8, 57.6, 18.9; Anal. Calcd. for
C18H16N6O: C, 65.05; H, 4.85; N, 25.29; O, 4.81, Found: C,
63.05; H, 3.85; N, 23.29; O, 4.85; ESI-MS (M+1): 333.14.
2.2.5.5. 4-((4-Methoxy-6-((4-nitrophenyl)amino)-1,3,5-tria-
zin-2-yl)amino)benzonitrile (6e). Yield: 68%; m.p. 171 C;
IR (KBr cm1): 3253 (NH), 1239 (C–O–C), 1349 (CN), 3055
(Aromatic CH str), 855 (s-triazine C–N str.); 1H NMR
(400 MHz, DMSO-d6): d 8.16 (d, J= 7.5 Hz, 2H), 7.60 (d,
J= 7.5 Hz, 2H), 7.27 (d, J= 7.5 Hz, 2H), 7.18 (d,
J= 7.5 Hz, 2H), 4.79 (s, 1H), 4.74 (s, 1H), 3.89 (s, 3H); 13C
NMR (100 MHz, DMSO-d6): d 192.0, 177.9, 162.8, 151.9,
144.8, 134.1, 132.5, 126.7, 119.2, 116.8, 113.1, 105.3, 58.2;
Anal. Calcd. for C17H13N7O3: C, 56.20; H, 3.61; N, 26.99;
O, 13.21, Found: C, 56.20; H, 3.61; N, 26.99; O, 13.21; ESI-
MS (M+1): 364.11.2.2.5.6. 4-((4-((4-Bromophenyl)amino)-6-methoxy-1,3,5-tria-
zin-2-yl)amino)benzonitrile (6f). Yield: 73%; m.p. 143 C;
IR (KBr cm1): 3254 (NH), 1230 (C–O–C), 1339 (CN), 3054
(Aromatic CH str), 850 (s-triazine C–N str.); 1H NMR
(400 MHz, DMSO-d6): d 7.69 (d, J= 7.5 Hz, 2H), 7.42 (d,
J= 7.5 Hz, 2H), 7.11 (d, J= 7.5 Hz, 2H), 6.87 (d,
J= 7.5 Hz, 2H), 5.65 (s, 1H), 4.46 (s, 1H), 3.81 (s, 3H); 13C
NMR (100 MHz, DMSO-d6): d 191.4, 180.7, 169.2, 156.5,
141.9, 136.6, 130.7, 125.1, 120.2, 117.6, 114.9, 107.1, 56.1;
Anal. Calcd. for C17H13BrN6O: C, 51.40; H, 3.30; Br, 20.12;
N, 21.16; O, 4.03, Found: C, 51.40; H, 3.35; Br, 20.05; N,
21.12; O, 4.04; ESI-MS (M+1): 397.03.
2.2.5.7. 4-((4-Methoxy-6-((4-methoxyphenyl)amino)-1,3,5-
triazin-2-yl)amino)benzonitrile (6g). Yield: 82%; m.p.
166 C; IR (KBr cm1): 3255 (NH), 1239 (C–O–C), 1347
(CN), 3055 (Aromatic CH str), 856 (s-triazine C–N str.); 1H
NMR (400 MHz, DMSO-d6): d 7.59 (d, J= 7.5 Hz, 2H),
7.17 (d, J= 7.5 Hz, 2H), 6.96 (d, J= 7.5 Hz, 2H), 6.85 (d,
J= 7.5 Hz, 2H), 4.58 (s, 1H), 4.31 (s, 1H), 3.86 (s, 3H), 3.82
(s, 3H); 13C NMR (100 MHz, DMSO-d6): d 195.1, 171.6,
164.4, 152.9, 144.8, 137.2, 1326, 125.2, 120.8, 118.1, 114.9,
105.5, 59.7, 54.2; Anal. Calcd. for C18H16N6O2: C, 62.06; H,
4.63; N, 24.12; O, 9.19, Found: C, 61.06; H, 4.60; N, 24.11;
O, 9.18; ESI-MS (M+1): 349.13.
2.2.6. General procedure of triazine based morpholine piperidine
and piperazine derivatives (7a–h)
To a stirred solution of 4-((4-chloro-6-methoxy-1,3,5-triazin-2-
yl)amino)benzonitrile 3 (5.0 g, 0.0191 mol) and sodium bicar-
bonate (1.77 g, .0210 mol) in acetone (10.0 mL), a solution of
appropriate piperazines or morpholine or piperidine
(0.0191 mol) in 5 mL acetone was added dropwise and reﬂuxed
for 4–5 h. The progress of reaction was monitored by TLC
using toluene:ethyl acetate (6:4) as an eluent. After the comple-
tion of the reaction, the reﬂuxed content was poured into
crushed ice. The solid product obtained was ﬁltered and dried.
The crude product was puriﬁed by crystallization from ethyl
acetate to get the title compound.
2.2.6.1. 4-((4-Methoxy-6-(4-methylpiperazin-1-yl)-1,3,5-tria-
zin-2-yl)amino)benzonitrile (7a). Yield: 76%; m.p. 139 C;
IR (KBr cm1): 3233 (NH), 1274 (C–O–C), 1325 (CN), 3048
(Aromatic CH str), 863 (s-triazine C–N str.); 1H NMR
(400 MHz, DMSO-d6): d 7.81 (d, J= 7.5 Hz, 2H), 7.18 (d,
J= 7.5 Hz, 2H), 4.48 (s, 1H), 3.85 (s, 3H), 3.69 (t,
J= 5.2 Hz, 2H), 3.55 (t, J= 5.2 Hz, 2H), 2.77 (t,
J= 5.1 Hz, 2H), 2.59 (t, J= 5.2 Hz, 2H), 2.34 (s, 3H); 13C
NMR (100 MHz, DMSO-d6): d 189.5, 172.4, 168.3, 142.7,
134.1, 120.9, 118.4, 105.6, 58.3, 50.8, 49.2, 45.7; Anal. Calcd.
for C16H19N7O: C, 59.06; H, 5.89; N, 30.13; O, 4.92, Found:
C, 58.06; H, 5.88; N, 30.12; O, 4.92; ESI-MS (M+1): 326.17.
2.2.6.2. 4-((4-(4-Ethylpiperazin-1-yl)-6-methoxy-1,3,5-triazin-
2-yl)amino)benzonitrile (7b). Yield: 69%; m.p. 156 C; IR
(KBr cm1): 3254 (NH), 1265 (C–O–C), 1339 (CN), 3024
(Aromatic CH str), 844 (s-triazine C–N str.); 1H NMR
(400 MHz, DMSO-d6): d 7.49 (d, J= 7.5 Hz, 2H), 7.14 (d,
J= 7.5 Hz, 2H), 4.41 (s, 1H), 3.89 (s, 3H), 3.67 (t,
J= 5.1 Hz, 2H), 3.52 (t, J= 5.2 Hz, 2H), 2.81 (t,
J= 5.2 Hz, 2H), 2.59–2.49 (m, 4H), 1.08 (t, J= 6.3 Hz,
14 N.S. Mewada et al.3H); 13C NMR (100 MHz, DMSO-d6): d 194.6, 176.1, 167.7,
145.6, 135.4, 120.2, 114.9, 105.3, 59.3, 55.6, 50.0, 45.1, 13.8;
Anal. Calcd. for C17H21N7O: C, 60.16; H, 6.24; N, 28.89; O,
4.71, Found: C, 65.16; H, 6.15; N, 28.89; O, 4.66; ESI-MS
(M+1): 340.18.
2.2.6.3. 4-((4-(4-Acetylpiperazin-1-yl)-6-methoxy-1,3,5-tria-
zin-2-yl)amino)benzonitrile (7c). Yield: 71%; m.p. 136 C;
IR (KBr cm1): 3240 (NH), 1270 (C–O–C), 1358 (CN), 3076
(Aromatic CH str), 821 (s-triazine C–N str.); 1H NMR
(400 MHz, DMSO-d6): d 7.67 (d, J= 7.5 Hz, 2H), 7.12 (d,
J= 7.5 Hz, 2H), 4.58 (s, 1H), 4.36–3.76 (m, 5H), 4.36–2.26
(m, 11H), 2.08 (s, 3H); 13C NMR (100 MHz, DMSO-d6): d
191.1, 177.9, 167.6, 162.9, 145.5, 134.9, 120.3, 115.1, 106.8,
58.4, 52.5, 46.9, 22.7; Anal. Calcd. for C17H19N7O2: C,
57.78; H, 5.42; N, 27.75; O, 9.06, Found: C, 58.78; H, 5.44;
N, 26.75; O, 9.06; ESI-MS (M+1): 354.16.
2.2.6.4. 4-((4-(4-Isopropylpiperazin-1-yl)-6-methoxy-1,3,5-
triazin-2-yl)amino)benzonitrile (7d). Yield: 84%; m.p.
157 C; IR (KBr cm1): 3245 (NH), 1271 (C–O–C), 1355
(CN), 3076 (Aromatic CH str), 850 (s-triazine C–N str.); 1H
NMR (400 MHz, DMSO-d6): d 7.65–7.51 (m, 2H), 7.25–7.10
(m, 2H), 4.48 (s, 1H), 3.87–3.83 (m, 3H), 3.71–3.67 (m, 2H),
3.58–3.54 (m, 2H), 3.16 (s, 1H), 2.79–2.75 (m, 2H), 2.63–2.59
(m, 2H), 1.18 – 1.05 (m, 6H); 13C NMR (100 MHz, DMSO-
d6): d 189.1, 172.9, 161.3, 149.4, 135.5, 121.8, 118.1, 104.9,
69.2, 58.4, 54.9, 50.7, 16.5; Anal. Calcd. for C18H23N7O: C,
61.17; H, 6.56; N, 27.74; O, 4.53, Found: C, 62.15; H, 6.56;
N, 25.74; O, 4.53; ESI-MS (M+1): 354.20.
2.2.6.5. 4-((4-Methoxy-6-(4-phenylpiperazin-1-yl)-1,3,5-tria-
zin-2-yl)amino)benzonitrile (7e). Yield: 67%; m.p. 164 C;
IR (KBr cm1): 3241 (NH), 1270 (C–O–C), 1358 (CN), 3076
(Aromatic CH str), 844 (s-triazine C–N str.); 1H NMR
(400 MHz, DMSO-d6): d 7.66 (d, J= 7.5 Hz, 2H), 7.17 (d,
J= 7.5 Hz, 2H), 7.11 (dd, J= 10.7, 4.4 Hz, 2H), 6.71–6.62
(m, 3H), 4.55 (s, 1H), 3.86 (s, 3H), 4.36–3.37 (m, 11H); 13C
NMR (100 MHz, DMSO-d6): d 195.8, 176.3, 165.2, 144.9,
141.6, 134.1, 130.9, 125.3, 119.7, 116.6, 112.1, 104.8, 59.5,
47.8, 46.1; Anal. Calcd. for C21H21N7O: C, 65.10; H, 5.46;
N, 25.31; O, 4.13, Found: C, 62.10; H, 5.45; N, 24.31; O,
4.10; ESI-MS (M+1): 388.18.
2.2.6.6. 4-((4-Methoxy-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)
amino)benzonitrile (7f). Yield: 73%; m.p. 148 C; IR (KBr
cm1): 3240 (NH), 1272 (C–O–C), 1355 (CN), 3176 (Aromatic
CH str), 823 (s-triazine C–N str.); 1H NMR (400 MHz,
DMSO-d6): d 7.58 (d, J= 7.5 Hz, 2H), 7.21 (d, J= 7.5 Hz,
2H), 4.61 (s, 1H), 3.86 (s, 3H), 3.84–3.39 (m, 2H), 3.31–2.74
(m, 2H), 2.17–1.53 (m, 6H); 13C NMR (100 MHz, DMSO-
d6): d 192.1, 177.2, 161.3, 148.9, 135.7, 120.8, 114.6, 104.2,
58.7, 55.1, 28.6, 23.2; Anal. Calcd. for C16H18N6O: C, 61.92;
H, 5.85; N, 27.08; O, 5.16, Found: C, 59.92; H, 5.83; N,
27.05; O, 5.14; ESI-MS (M+1): 311.15.
2.2.6.7. 4-((4-Methoxy-6-morpholino-1,3,5-triazin-2-yl)amino)
benzonitrile (7g). Yield: 64%; m.p. 152 C; IR (KBr cm1):
3249 (NH), 1270 (C–O–C), 1358 (CN), 3077 (Aromatic CH
str), 821 (s-triazine C–N str.); 1H NMR (400 MHz, DMSO-
d6): d 7.66 (d, J= 7.5 Hz, 2H), 7.16 (d, J= 7.5 Hz, 2H),
4.51 (s, 1H), 3.86 (s, 3H), 3.78 (t, J= 4.8 Hz, 4H), 3.54 (t,J= 4.9 Hz, 2H), 3.43 (t, J= 4.8 Hz, 2H); 13C NMR
(100 MHz, DMSO-d6): d 187.1, 169.4, 162.3, 148.4, 139.6,
121.5, 118.3, 107.6, 67.5, 55.3, 48.2; Anal. Calcd. for
C15H16N6O2: C, 61.92; H, 5.85; N, 27.08; O, 5.16, Found:
C, 58.68; H, 5.12; N, 24.91; O, 10.25; ESI-MS (M+1):
313.13.
2.2.6.8. 4-((4-Methoxy-6-(4-(4-methoxyphenyl)piperazin-1-
yl)-1,3,5-triazin-2-yl)amino)benzonitrile (7h). Yield: 78%;
m.p. 133 C; IR (KBr cm1): 3249 (NH), 1270 (C–O–C),
1358 (CN), 3074 (Aromatic CH str), 825 (s-triazine C–N
str.); 1H NMR (400 MHz, DMSO-d6): d 7.58 (d, J= 7.5 Hz,
2H), 7.19 (d, J= 7.3 Hz, 2H), 6.72 (d, J= 7.5 Hz, 2H), 6.65
(d, J= 7.5 Hz, 2H), 4.54 (s, 1H), 3.86 (s, 3H), 4.36 – 3.52
(m, 14H); 13C NMR (100 MHz, DMSO-d6): d 189.9, 173.8,
169.2, 156.4, 146.2, 142.3, 134.5, 127.7, 119.6, 114.9, 112.6,
108.3, 59.1, 56.8, 49.2, 44.5; Anal. Calcd. for C22H23N7O2:
C, 63.30; H, 5.55; N, 23.49; O, 7.67, Found: C, 60.30; H,
5.55; N, 22.49; O, 7.65; ESI-MS (M+1): 418.19.
2.3. Biological assays
2.3.1. In vitro antimicrobial assays
A stock solution of the ﬁnal synthesized compounds (200 lg/
ml) was prepared in dimethyl sulfoxide and test compounds
were taken in a speciﬁed quantity of molten sterile agar, i.e.,
nutrient agar and dextrose agar for antibacterial and for anti-
fungal screening, respectively. Such medium enclosing the test
compound was poured into a Petri dish at a depth of 4–5 mm
and allowed to solidify under aseptic conditions. A suspension
of the respective microorganism of 105 CFU/ml was prepared
and added to plates with serially diluted compounds with con-
centrations in the range of 3.12–200 lg/ml in dimethyl sulfox-
ide and incubated at (37 ± 1) C temperature for 24 h
(bacteria) or 48 h (fungi). Minimum concentration of the sub-
stance that prevents the development of visible growth is con-
sidered to be the MIC value.
2.3.2. In vitro antituberculosis assays
The Mycobacteria Growth Indicator Tubes (MGIT) contain-
ing 4 ml of modiﬁed Middle brook 7H9 Broth Base were num-
bered as per the ﬁnal compounds to be tested for
antituberculosis activity by means of various concentrations
prepared. The solution was allowed to sit for 20 min, and
the tubes were centrifuged at 3000 rpm for 15–20 min. After
that about 104–107 CFU/ml of H37RV M. tuberculosis strain
suspension was added into the medium to be incubated. The
MGIT tubes were then closed tightly, stirred well and incu-
bated in a BACTECMGIT instrument at 37 C until positivity
is observed. The readings were measured from the second day
of incubation onwards. Positive cultures were generally
detected within 10 days. To observe actual results, the MGIT
tubes were removed from incubator and placed under the
UV light. Bright ﬂuorescence perceived by the corresponding
MGIT tube was noticed in the form of bright orange color
in the bottom of the tube showing an orange reﬂection on
the meniscus. The primary screening was carried out at con-
centration of 12.5 lg/ml against M. tuberculosis H37RV in
BACTEC MGIT system. Compounds possessing 99% inhibi-
tion in the primary screen were described as most active
compounds.
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3.1. Chemistry
The designed library of target compounds and respective inter-
mediates were synthesized as outlined in Scheme. The ﬁrst step
comprises the nucleophilic substitution of ﬁrst chlorine atom
of cyanuric chloride (1) by methanol to give 2,4-dichloro-6-
methoxy-1,3,5-triazine (2) intermediate with an efﬁcient yield.
Appearance of IR absorption peak at 2820 cm1 conﬁrms the
presence of the methoxy group in s-triazine. The intermediate
4-((4-chloro-6-methoxy-1,3,5-triazin-2-yl)amino)benzonitrile
(3) was achieved by condensation of compound (2) with
4-amino benzonitrile. It displayed absorption band at
2235 cm1 and 3294 cm1 and showed the attachment of
cyano and 2 amine group.
The target compound, third chlorine atom of cyanuric chlo-
ride was replaced by various substituted phenol, thiophenol,
aniline and piperazine/piperidine/morpholine derivatives using
appropriate solvents and formed ﬁnal 4a–j, 5a–j, 6a–g and 7a–
h compounds respectively which were further characterized by
FT-IR, 1H NMR, 13C NMR, Mass and elemental analyses.
Compounds 4a–j’s derivatives endowing thiophenol substitu-
ents were conﬁrmed by peaks at 1120 cm1; phenol substitu-
ents of 5a–j were veriﬁed by characteristic –C–O– stretching
peaks at 1210 cm1. Additional proton peak of –NH, in 1H
NMR, conﬁrmed the substitution with aniline derivatives in
the formation of 6a–g compounds whereas besides of –OCH3
peak, 1H NMR spectra of 7a–h compounds appeared with dis-
tinguishable –CH2–N–CH2– peaks in the range from 3.70 to
3.51 ppm.
3.2. Biological evaluation
All the synthesized compounds (4a–j, 5a–j, 6a–g and 7a–h)
were examined for their antibacterial activities (against four
strains of bacteria- Staphylococcus aureus MTCC 96, Bacillus
cereusMTCC 430, Escherichia coliMTCC 739, and Pseudomo-
nas aeruginosa MTCC 741) and antifungal activities (against
three strains of fungi- Candida albicansMTCC 183, Aspergillus
niger MTCC 282, and Aspergillus clavatus MTCC 1323) using
the broth dilution technique (Hawkey and Lewis, 2004) and
were also checked for their antituberculosis activity (against
M. tuberculosis H37Rv) using the BACTEC MGIT method
as reported earlier (Isenberg and Microbiology, 1992).
Ciproﬂoxacin and ketoconazole were used as standard drugs
for antibacterial and antifungal activities, respectively, whereas
isoniazid, rifampicin, ethambutol and pyrazinamide are used
as standard drugs for antituberculosis activity.
3.2.1. In vitro antibacterial activity
Table 1 shows that all synthesized compounds exhibited well
to moderate activity, among them, the chloro group containing
moiety 4d was found to be highly active for the bacterial strain
B. cereus MTCC 430. The electron donating group i.e. methyl
group containing compound 4g was found superior to others
against the bacterial species E. coli MTCC 739. Compounds
4i and 4j possessing the ﬂuoro group exhibited excellent inhib-
itory proﬁle against the bacterial strains P. aeruginosa MTCC
741 and S. aureus MTCC 96 respectively. Compound 4c
having the chloro group showed very good efﬁcacy for thestrain B. cereus MTCC 430. Another moieties possessing the
chloro group i.e. 4c and 4d were found to be active for the bac-
terial strains P. aeruginosaMTCC 741 and S. aureusMTCC 96
respectively. The ﬂuorinated compounds 4h and 4i showed
excellent inhibitory proﬁle for the bacterial strains S. aureus
MTCC 96 and B. cereus MTCC 430, respectively. Again com-
pounds 4i and 4j also exhibited potent inhibitory proﬁle
against the bacterial strains, E. coli MTCC 739 and B. cereus
MTCC 430, respectively. Antibacterial efﬁcacy study showed
that out of the compounds 5a–j, compound 5e endowed with
the ﬂuoro group was only found to be highly potent for the
bacterial strain P. aeruginosa MTCC 741. Compounds 5e
and 5g possessing the ﬂuoro group displayed potent inhibitory
proﬁle for the strains S. aureusMTCC 96 and B. cereusMTCC
430, respectively. The chloro group containing scaffolds i.e. 5h,
5i and 5j also gave very good antibacterial activity against the
strains, B. cereusMTCC 430, E. coliMTCC 739, and S. aureus
MTCC 96, respectively. Among the synthesized scaffolds 6a–g,
compounds 6c and 6f which have the halogen group were
found to exhibit excellent inhibitory effect on the bacterial
strains B. cereus MTCC 430 and P. aeruginosa MTCC 741,
respectively. The chlorinated moiety 6b was also found to be
active against the bacterial species B. cereus MTCC 430. The
methyl group containing scaffold i.e. 6d showed very good
antibacterial activity against the bacterium E. coli MTCC
739. The brominated compound 6f exhibited excellent inhibi-
tory effect on the bacterial strain S. aureus MTCC 96. Com-
pound 6g possessing the methoxy group was found to be
active for both the bacterial strains, S. aureus MTCC 96 and
E. coli MTCC 739. The antibacterial activity study of com-
pounds 7a–h revealed that there are three triazine moieties
which exhibited superior antibacterial efﬁcacy against the spe-
ciﬁc strain of bacteria. Compound 7c having the N-acetyl
group was found to be highly potent against the bacterial
strain S. aureus MTCC 96. Compound 7e endowed with N-
phenyl piperazinyl molecule was found superior to other with
respect to inhibiting the growth of P. aeruginosaMTCC 741. A
triazine scaffold 7h having p-methoxy phenyl piperazinyl entity
gave excellent inhibitory effect on the bacterial strain E. coli
MTCC 739. The N-isopropyl piperazinyl triazine moiety 7d
was found as a potent antibacterial agent against both the
strains B. cereus MTCC 430 and P. aeruginosa MTCC 741.
A piperidinyl substituted triazine derivative 7f showed good
efﬁciency against both the bacterial strains S. aureus MTCC
96 and E. coliMTCC 739. The morpholine substituted triazine
scaffold 7g exhibited potent antibacterial activity for both the
strains S. aureus MTCC 96 and P. aeruginosa MTCC
741. Compound 7h also showed potency against the strain
P. aeruginosa MTCC 741.
3.2.2. In vitro antifungal activity
All synthesized triazine scaffolds were examined for their anti-
fungal potency, which is outlined in Table 2 shows that com-
pounds having the halogen group exhibited highly potential
antifungal efﬁcacy against speciﬁc strain of fungi. The
chlorinated moieties 4c and 4d displayed excellent inhibitory
proﬁle against the fungal strains C. albicans MTCC 183 and
A. clavatus MTCC 1323, respectively. The compound contain-
ing the ﬂuoro group i.e. 4i was found to be highly active for the
strain A. nigerMTCC 282. Another chlorinated moiety 4b also
showed very good antifungal activity against the strain A. niger
MTCC 282. Compound 4d was also found to be active against
Table 1 In vitro antimicrobial activity of compounds 4a–j, 5a–
j, 6a–g and 7a–h.
Compound R/X MIC (lg/mL)
Gram +ve Gram ve
S.a B.c E.c P.a
MTCC
96
MTCC
430
MTCC
739
MTCC
741
4a H 200 50 100 25
4b 2-Cl 25 100 12.5 50
4c 3-Cl 50 6.25 50 12.5
4d 4-Cl 12.5 3.12 200 100
4e 2-CH3 100 200 25 50
4f 3-CH3 200 200 100 25
4g 4-CH3 50 25 3.12 200
4h 2-F 6.25 100 50 100
4i 3-F 25 6.25 12.5 3.12
4j 4-F 3.12 12.5 50 25
5a H 200 50 200 100
5b 2-CH3 100 200 25 50
5c 3-CH3 100 100 50 200
5d 4-CH3 50 200 100 50
5e 2-F 12.5 25 200 3.12
5f 3-F 50 50 200 100
5g 4-F 25 12.5 50 25
5h 2-Cl 100 12.5 25 100
5i 3-Cl 25 25 12.5 50
5j 4-Cl 12.5 100 50 50
6a H 200 50 100 200
6b 2-Cl 50 12.5 200 25
6c 3-Cl 100 3.12 200 50
6d 2-CH3 25 50 6.25 100
6e 4-NO2 200 100 100 50
6f 4-Br 6.25 200 50 3.12
6g 4-OCH3 12.5 200 12.5 25
7a X=N–CH3 100 50 200 25
7b N–CH2CH3 50 100 200 50
7c N–COCH3 3.12 200 100 100
7d N–CH(CH3)2 200 6.25 25 12.5
7e N–C6H5 200 25 50 3.12
7f –CH2– 12.5 100 6.25 100
7g –O– 6.25 200 100 12.5
7h N–C6H4–OCH3 50 200 3.12 6.25
Cip. – 1.72 0.28 1.40 0.62
DMSO – – – – –
MIC=Minimum inhibitory concentration, Cip. ciproﬂoxacin, S.a
Staphylococcus aureus, B.c Bacillus cereus, E.c Escherichia coli, P.a
Pseudomonas aeruginosa.
Bold values indicates superior minimum inhibition concentration
against particular microbial strain.
Table 2 In vitro antifungal activity of compounds 4a–j, 5a–j,
6a–g and 7a–h.
Compound R/X MIC (lg/mL)
C.a A.n A.c
MTCC
183
MTCC
282
MTCC
1323
4a H 100 200 12.5
4b 2-Cl 50 6.25 100
4c 3-Cl 3.12 100 50
4d 4-Cl 12.5 50 3.12
4e 2-CH3 25 100 200
4f 3-CH3 100 25 50
4g 4-CH3 200 50 100
4h 2-F 50 12.5 100
4i 3-F 25 3.12 12.5
4j 4-F 12.5 25 25
5a H 200 100 25
5b 2-CH3 50 6.25 200
5c 3-CH3 100 50 100
5d 4-CH3 25 12.5 25
5e 2-F 100 100 50
5f 3-F 12.5 25 25
5g 4-F 50 200 100
5h 2-Cl 200 100 200
5i 3-Cl 12.5 50 6.25
5j 4-Cl 6.25 200 25
6a H 200 100 50
6b 2-Cl 50 200 12.5
6c 3-Cl 6.25 25 200
6d 2-CH3 100 6.25 200
6e 4-NO2 25 50 50
6f 4-Br 200 100 3.12
6g 4-OCH3 12.5 200 25
7a X=N–CH3 100 200 12.5
7b N–CH2CH3 100 100 25
7c N–COCH3 3.12 50 6.25
7d N–CH(CH3)2 25 50 50
7e N–C6H5 6.25 12.5 100
7f –CH2– 200 3.12 200
7g –O– 200 6.25 12.5
7h N–C6H4–OCH3 50 100 6.25
Kit. – 1.56 1.56 0.78
DMSO – – – –
Kit. ketoconazole, C.a. Candida albicans, A.n. Aspergillus niger,
A.c. Aspergillus clavatus.
Bold values indicates superior minimum inhibition concentration
against particular microbial strain.
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4h, 4i and 4j exhibited good antifungal efﬁcacy against the fun-
gal strains A. niger MTCC 282, A. clavatus MTCC 1323, and
C. albicans MTCC 183, respectively. Antifungal activity
Table 2 revealed that none of the compound of 5a-j exhibited
highly potent activity against the fungal strains. However,
some of them were found to be active for the speciﬁc fungal
species into some extent. Among which, the methyl group con-
taining entities, both 5b and 5d showed good potency against
the strain A. niger MTCC 282. The ﬂuoro group containing
scaffold 5f gave inhibitory effect to the strain C. albicans
MTCC 183. Compounds 5i and 5j were found to be active
for the strains A. clavatus MTCC 1323 and C. albicans MTCC183, respectively. The chlorinated compound 5i also gave
inhibitory effect on the growth of the fungal strain C. albicans
MTCC 183. Among the series of compounds 6a–g, the bromo
group containing entity 6f was found superior to others against
A. clavatus MTCC 1323. Compounds 6b and 6c having the
chloro group gave good antifungal activity against the fungal
strains A. clavatus MTCC 1323 and C. albicans MTCC 183,
respectively. The electron donating methyl group possessing
moiety 6d was found to be highly active for the strain A. niger
MTCC 282. The study of compound 7a–h indicates that the
triazine scaffold substituted with N-acetyl piperazine i.e. 7c
exhibited excellent inhibitory proﬁle for the fungal strain C.
albicans MTCC 183. A piperidinyl derivative of triazine i.e.
7f displayed a highly potent inhibitory effect on the strain A.
niger MTCC 282. Compound 7a, an N-methyl piperazine
Table 3 In vitro antituberculosis activity of compounds 4a–j,
5a–j, 6a–g and 7a–h.
Compound R/X BACTEC MGIT method a
MIC lg/ml % Inhibition
4a H >12.5 –
4b 2-Cl 12.5 95
4c 3-Cl >12.5 –
4d 4-Cl >12.5 –
4e 2-CH3 >12.5 –
4f 3-CH3 >12.5 –
4g 4-CH3 12.5 95
4h 2-F >12.5 –
4i 3-F 12.5 95
4j 4-F >12.5 –
5a H >12.5 –
5b 2-CH3 >12.5 –
5c 3-CH3 >12.5 –
5d 4-CH3 >12.5 –
5e 2-F >12.5 –
5f 3-F >12.5 –
5g 4-F >12.5 –
5h 2-Cl >12.5 –
5i 3-Cl >12.5 –
5j 4-Cl >12.5 –
6a H >12.5 90
6b 2-Cl 12.5 95
6c 3-Cl >12.5 92
6d 2-CH3 >12.5 90
6e 4-NO2 >12.5 90
6f 4-Br >12.5 91
6g 4-OCH3 >12.5 90
7a X=N–CH3 >12.5 91
7b N–CH2CH3 >12.5 92
7c N–COCH3 >12.5 93
7d N–CH(CH3)2 12.5 95
7e N–C6H5 >12.5 92
7f –CH2– >12.5 93
7g –O– >12.5 94
7h N–C6H4–OCH3 12.5 95
Isoniazid – 0.20 99
Rifampicin – 0.25 99
Ethambutol – 3.12 99
Pyrazinamide – 6.25 99
a Each value is the mean of three independent experiments.
Bold values indicates superior minimum inhibition concentration
against particular microbial strain.
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against A. clavatus MTCC 1323. Again compound 7c gave
very good inhibiting effect on A. clavatus MTCC 1323. Com-
pound 7e endowed with N-phenyl piperazinyl molecule
showed very high potency to inhibit the growth of both the
fungal strains C. albicans MTCC 183 and A. niger MTCC
282. The morpholine derivative of triazine i.e. 7g displayed
high potency for both the strains A. niger MTCC 282 and A.
clavatus MTCC 1323. The triazine scaffold incorporated with
N-(4-methoxy phenyl) piperazinyl derivative i.e. 7h was found
to be highly potent against the fungal strain A. clavatusMTCC
1323.
3.2.3. In vitro antituberculosis activity
Further all the synthesized triazine scaffolds were examined for
their antituberculosis activities against the tubercular strainM.
tuberculosis H37Rv using the BACTEC MGIT method. The
results for this study show that the thiophenol substituted tri-
azine scaffolds incorporated with the halogen group i.e. 4b and
4i were found to be highly active against the mentioned tuber-
cular strain. The electron donating methyl group containing
scaffold 4g also showed high effectiveness against the myco-
bacterium species. The study of antituberculosis activity
(Table 3) indicates that among the series of compounds 5a-j,
none of the compound was active to inhibit the growth of
strain. The chlorinated triazine scaffold 6b was found to give
superior antibacterial efﬁcacy. The triazine molecule endowed
with N-isopropyl piperazinyl derivative i.e. 7d exhibited potent
antibacterial proﬁle. The compound containing N-(4-methoxy
phenyl)piperazinyl moiety i.e. 7h was also found to be effective
in inhibiting the growth of the above mentioned tubercular
species.
3.2.4. SAR (structure–activity relationship)
3.2.4.1. Antibacterial activity. Among all synthesized com-
pounds, possessing thiophenol moiety appeared with better
antibacterial activity. Interestingly, halogen substitution at
para position of thio-phenol ring provides good efﬁciency
against Gram +ve bacteria. When the position of this substi-
tuent is replaced with meta, it showed promising activity
against Gram ve bacterial strain. Meanwhile instead of thio-
phenol ring, incorporation of phenol, amine or piperazine ring
deviated the microbial activity but not up to the mark. The
presence of two nitrogen atoms in piperazine ring with electron
withdrawing acetyl group increases the biological potential
than aniline and phenol substituted compounds.
3.2.4.2. Antifungal activity. Only halogen substituted thiophe-
nol compounds provided good inhibition growth of fungal
strains. Compared to other compounds, piperazine with acetyl
group showed excellent antifungal activity as shown for
bacterial strains as well. Phenol substituted derivatives were
not as active as arylamino substituted compounds among
which 4-ﬂuoro substituent appeared with good inhibition.
3.2.4.3. Anti-tuberculosis activity. Halogen at ortho and meta
position of thiophenol ring showed about 95% inhibition of
H37Rv strain and methyl substituent at para position provided
same activity with less MIC values. Isopropyl and anisole sub-
stituent in piperazine ring showed better anti-tuberculosis
activity than the rest of the compounds. Unfortunately, none
of the phenol substituted derivatives showed % inhibition oftuberculosis strain however, ortho substituted chloro group
in aniline exhibited excellent inhibition. Nevertheless, rest of
the compounds appeared with good to moderate activity due
to variation of substituent positions. These positional isomers
may affect the potency of titled compounds and hence devia-
tion of biological activity as well.
4. Conclusion
The present work is basically focused on the development of
novel s-triazinyl derivatives with wide therapeutic windows.
Out of 35 compounds screened, majority of the compounds
came out with promising activity against a wide range of path-
ogenic bacteria, fungi and mycobacteria. From the bioassay
results, it was also possible to make a number of correlations
18 N.S. Mewada et al.regarding the relationship between the structure of the newer
scaffolds and their antimicrobial activities. The thiophenol
derivatives bearing chloro and ﬂuoro were found to be the
most active among the four series of ﬁnal s-triazine based
congeners. Marking on this order, piperazine substituted com-
pounds displayed better activity than aniline and phenol
substituted derivatives. N-acetyl (7c) with 3.12 lg/mL of
MIC and N-(4-methyl phenoxy) (7h) analogous emerged as
potential agents against bacteria and M. tuberculosis H37Rv
strain as well. These privileged structures with enhanced bioac-
tivities lead to provide enough scope to develop new scaffolds
for further drug discovery process.
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